|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
|
US4741900A
(en)
|
1982-11-16 |
1988-05-03 |
Cytogen Corporation |
Antibody-metal ion complexes
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
GB8430252D0
(en)
|
1984-11-30 |
1985-01-09 |
Beecham Group Plc |
Compounds
|
|
US5206344A
(en)
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
EP0245993B1
(en)
|
1986-04-28 |
1993-05-26 |
Cetus Oncology Corporation |
Monoclonal antibodies against c5a and des-arg74-c5a, their production and use
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US5256642A
(en)
|
1988-04-01 |
1993-10-26 |
The Johns Hopkins University |
Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
|
|
NZ230747A
(en)
|
1988-09-30 |
1992-05-26 |
Bror Morein |
Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5166322A
(en)
|
1989-04-21 |
1992-11-24 |
Genetics Institute |
Cysteine added variants of interleukin-3 and chemical modifications thereof
|
|
US5244800A
(en)
|
1990-04-27 |
1993-09-14 |
The Uab Research Foundation |
Crystals of human complement factor d that are triclinic
|
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
WO1993000109A1
(en)
|
1991-06-28 |
1993-01-07 |
Genentech, Inc. |
Method of stimulating immune response using growth hormone
|
|
FI941572L
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
|
|
AU675929B2
(en)
|
1992-02-06 |
1997-02-27 |
Curis, Inc. |
Biosynthetic binding protein for cancer marker
|
|
US5456909A
(en)
|
1992-08-07 |
1995-10-10 |
T Cell Sciences, Inc. |
Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
|
|
WO1994004188A1
(en)
|
1992-08-21 |
1994-03-03 |
Genentech, Inc. |
Method for treating an lfa-1-mediated disorder
|
|
EP0679095A1
(en)
|
1992-11-25 |
1995-11-02 |
Amgen Boulder Inc. |
Modified insulin-like growth factors
|
|
US5861156A
(en)
|
1993-01-08 |
1999-01-19 |
Creative Biomolecules |
Methods of delivering agents to target cells
|
|
FI954805A7
(fi)
|
1993-04-07 |
1995-11-15 |
Amgen Boulder Inc |
Menetelmiä insuliininkaltaisen kasvutekijän sitojaproteiinien käyttämi seksi
|
|
US5856300A
(en)
|
1994-05-12 |
1999-01-05 |
T Cell Sciences, Inc. |
Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
|
|
US5679546A
(en)
|
1993-09-24 |
1997-10-21 |
Cytomed, Inc. |
Chimeric proteins which block complement activation
|
|
US5627264A
(en)
|
1994-03-03 |
1997-05-06 |
Alexion Pharmaceuticals, Inc. |
Chimeric complement inhibitor proteins
|
|
AU2191795A
(en)
|
1994-03-23 |
1995-10-09 |
Alexion Pharmaceuticals, Inc. |
Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation
|
|
US5534615A
(en)
|
1994-04-25 |
1996-07-09 |
Genentech, Inc. |
Cardiac hypertrophy factor and uses therefor
|
|
US5919623A
(en)
|
1994-04-27 |
1999-07-06 |
St. James's And Seacroft University Hospitals Nhs Trust |
Nucleic acid mutation assays
|
|
US6074642A
(en)
|
1994-05-02 |
2000-06-13 |
Alexion Pharmaceuticals, Inc. |
Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
|
|
US5679345A
(en)
|
1994-06-02 |
1997-10-21 |
The Johns Hopkins University |
Method for preventing complement-dependent rejection of organ or tissue transplants
|
|
WO2001004311A1
(en)
|
1999-07-07 |
2001-01-18 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
US5897475A
(en)
|
1994-10-05 |
1999-04-27 |
Antex Biologics, Inc. |
Vaccines comprising enhanced antigenic helicobacter spp.
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
|
CA2230492C
(en)
|
1995-09-21 |
2009-05-26 |
Genentech, Inc. |
Human growth hormone variants
|
|
WO2002000690A2
(en)
|
2000-06-23 |
2002-01-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
|
US7122636B1
(en)
|
1997-02-21 |
2006-10-17 |
Genentech, Inc. |
Antibody fragment-polymer conjugates and uses of same
|
|
US20050197285A1
(en)
|
1997-03-07 |
2005-09-08 |
Rosen Craig A. |
Human secreted proteins
|
|
US6472520B2
(en)
|
1997-03-21 |
2002-10-29 |
The Trustees Of Columbia University In The City Of New York |
Rat PEG-3 promoter
|
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
|
JP3957765B2
(ja)
|
1997-04-07 |
2007-08-15 |
ジェネンテク・インコーポレイテッド |
抗ｖｅｇｆ抗体
|
|
US5994511A
(en)
*
|
1997-07-02 |
1999-11-30 |
Genentech, Inc. |
Anti-IgE antibodies and methods of improving polypeptides
|
|
ATE375363T1
(de)
|
1997-07-14 |
2007-10-15 |
Bolder Biotechnology Inc |
Derivate des wachstumshormons und verwandte proteine
|
|
AU756490B2
(en)
|
1997-08-26 |
2003-01-16 |
Abgenix, Inc. |
A process for inhibiting complement activation via the alternative pathway
|
|
US6410708B1
(en)
|
1997-11-21 |
2002-06-25 |
Genentech, Inc. |
Nucleic acids encoding A-33 related antigen polypeptides
|
|
US8088386B2
(en)
|
1998-03-20 |
2012-01-03 |
Genentech, Inc. |
Treatment of complement-associated disorders
|
|
ES2288649T3
(es)
|
1997-11-21 |
2008-01-16 |
Genentech, Inc. |
Antigenos tipo a-33 y sus utilizaciones farmacologicas.
|
|
US7192589B2
(en)
|
1998-09-16 |
2007-03-20 |
Genentech, Inc. |
Treatment of inflammatory disorders with STIgMA immunoadhesins
|
|
US7282565B2
(en)
|
1998-03-20 |
2007-10-16 |
Genentech, Inc. |
PRO362 polypeptides
|
|
US8007798B2
(en)
|
1997-11-21 |
2011-08-30 |
Genentech, Inc. |
Treatment of complement-associated disorders
|
|
US7419663B2
(en)
|
1998-03-20 |
2008-09-02 |
Genentech, Inc. |
Treatment of complement-associated disorders
|
|
US7005504B2
(en)
|
1998-01-22 |
2006-02-28 |
Genentech, Inc. |
Antibody fragment-peg conjugates
|
|
EP1053245A4
(en)
|
1998-02-09 |
2002-04-17 |
Human Genome Sciences Inc |
45 HUMAN SECRETED PROTEINS
|
|
US6956107B2
(en)
|
1998-02-20 |
2005-10-18 |
Tanox, Inc. |
Inhibitors of complement activation
|
|
US7112327B2
(en)
|
1998-02-20 |
2006-09-26 |
Tanox, Inc. |
Inhibition of complement activation
|
|
BR9909220A
(pt)
|
1998-02-20 |
2000-11-21 |
Tanox Inc |
Inibidores de ativação de complemento
|
|
JP3868740B2
(ja)
|
1998-03-10 |
2007-01-17 |
ジェネンテック・インコーポレーテッド |
新規なポリペプチド及びそれをコードする核酸
|
|
AU5587799A
(en)
|
1998-08-27 |
2000-03-21 |
Incyte Pharmaceuticals, Inc. |
Protein transport-associated molecules
|
|
US6376653B1
(en)
|
1998-09-28 |
2002-04-23 |
Smithkline Beecham Plc |
Tie2 antagonist antibodies
|
|
KR100468978B1
(ko)
|
1998-12-16 |
2005-02-02 |
제넨테크, 인크. |
분비 및 막횡단 폴리펩티드, 및 이를 코딩하는 핵산
|
|
JP3993746B2
(ja)
|
1998-12-22 |
2007-10-17 |
ジェネンテック・インコーポレーテッド |
腫瘍性細胞成長阻害のための組成物及び方法
|
|
HU230769B1
(hu)
|
1999-01-15 |
2018-03-28 |
Genentech Inc. |
Módosított effektor-funkciójú polipeptid-változatok
|
|
CA2362427A1
(en)
|
1999-03-08 |
2000-09-14 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
NZ514091A
(en)
|
1999-03-11 |
2004-01-30 |
Rmf Dictagene S |
Vascular adhesion molecules and modulation of their function
|
|
US6642353B1
(en)
|
1999-03-17 |
2003-11-04 |
Chugai Seiyaku Kabushiki Kaisha |
Peptide ligands for the erythropoietin receptor
|
|
JP2003514541A
(ja)
|
1999-11-19 |
2003-04-22 |
ヒューマン ジノーム サイエンシーズ， インコーポレイテッド |
１８個のヒト分泌タンパク質
|
|
EP1672070A3
(en)
|
1999-12-01 |
2006-10-04 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
CA2399969A1
(en)
|
2000-02-10 |
2001-08-16 |
Alexion Pharmaceuticals, Inc. |
Mixtures of caspase inhibitors and complement inhibitors and methods of use thereof
|
|
US6821775B1
(en)
|
2000-02-11 |
2004-11-23 |
Genvec, Inc. |
Viral vector encoding pigment epithelium-derived factor
|
|
AU2001249410A1
(en)
|
2000-03-23 |
2001-10-03 |
Tanox, Inc. |
Anti-c2/c2a inhibitors of complement activation
|
|
AU2001261103B2
(en)
|
2000-04-29 |
2007-08-23 |
University Of Iowa Research Foundation |
Diagnostics and therapeutics for macular degeneration-related disorders
|
|
CA2416538A1
(en)
|
2000-07-20 |
2002-01-31 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
|
AU2001296594A1
(en)
|
2000-10-10 |
2002-04-22 |
Tanox, Inc. |
Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
|
|
AU2002213441B2
(en)
|
2000-10-12 |
2006-10-26 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
|
MXPA03003144A
(es)
|
2000-10-13 |
2004-12-06 |
Biogen Inc |
Anticuerpos humanizados anti-lt-??-r.
|
|
NZ526720A
(en)
|
2000-12-28 |
2007-11-30 |
Altus Pharmaceuticals Inc |
Crystallisation of whole antibodies or fragments thereof, on a large scale and a process allowing an alternative route for delivery of therapeutic antibodies
|
|
US20040077575A1
(en)
|
2002-01-11 |
2004-04-22 |
Giordano Giovan Giacomo |
Inhibition of pathological angiogenesis in vivo
|
|
US6867189B2
(en)
|
2001-07-26 |
2005-03-15 |
Genset S.A. |
Use of adipsin/complement factor D in the treatment of metabolic related disorders
|
|
BRPI0211953B8
(pt)
|
2001-08-17 |
2021-05-25 |
Genentech Inc |
anticorpo monoclonal ou fragmento de ligação a antígeno que se liga a c5 e c5a sem a prevenção da formação de c5b, linhagem celular, composição farmacêutica, bem como método in vitro para inibir a atividade de c5a e método de diagnóstico in vitro
|
|
IL161051A0
(en)
|
2001-10-02 |
2004-08-31 |
Genentech Inc |
Apo-2 ligand variants and uses thereof
|
|
CA2489348A1
(en)
|
2002-06-24 |
2003-12-31 |
Genentech, Inc. |
Apo-2 ligand/trail variants and uses thereof
|
|
AU2003294210A1
(en)
|
2002-07-31 |
2004-05-04 |
Seattle Genetics, Inc |
Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
|
|
TWI323265B
(en)
|
2002-08-06 |
2010-04-11 |
Glaxo Group Ltd |
Antibodies
|
|
WO2004022594A2
(en)
|
2002-09-06 |
2004-03-18 |
Cytos Biotechnology Ag |
Immune modulatory compounds and methods
|
|
US7816497B2
(en)
|
2002-10-30 |
2010-10-19 |
University Of Kentucky |
Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
|
|
WO2004041160A2
(en)
|
2002-10-30 |
2004-05-21 |
University Of Kentucky Research Foundation |
Methods and animal model for analyzing age-related macular degeneration
|
|
AU2004216176B2
(en)
|
2003-02-21 |
2008-04-03 |
Genentech, Inc. |
Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
|
|
RU2232991C1
(ru)
|
2003-04-09 |
2004-07-20 |
Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" |
Способ определения функциональной активности фактора d комплемента человека
|
|
KR100512483B1
(ko)
|
2003-05-07 |
2005-09-05 |
선바이오(주) |
신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법
|
|
US7709610B2
(en)
|
2003-05-08 |
2010-05-04 |
Facet Biotech Corporation |
Therapeutic use of anti-CS1 antibodies
|
|
CN1845938B
(zh)
|
2003-06-30 |
2010-05-26 |
杜门蒂斯有限公司 |
多肽
|
|
EP2267028A3
(en)
|
2003-06-30 |
2011-07-27 |
Domantis Limited |
Dual specific single domain antibodies (dAb) conjugated to PEG
|
|
WO2005014849A2
(en)
|
2003-07-03 |
2005-02-17 |
Euro-Celtique, S.A. |
Genes associated with responses to neuropathic pain
|
|
WO2005044853A2
(en)
|
2003-11-01 |
2005-05-19 |
Genentech, Inc. |
Anti-vegf antibodies
|
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
|
WO2005025509A2
(en)
|
2003-09-11 |
2005-03-24 |
Board Of Regents, The University Of Texas System |
Methods and materials for treating autoimmune diseases and conditions
|
|
US20050169921A1
(en)
|
2004-02-03 |
2005-08-04 |
Leonard Bell |
Method of treating hemolytic disease
|
|
US20090087854A1
(en)
|
2007-09-27 |
2009-04-02 |
Perlegen Sciences, Inc. |
Methods for genetic analysis
|
|
US7127355B2
(en)
|
2004-03-05 |
2006-10-24 |
Perlegen Sciences, Inc. |
Methods for genetic analysis
|
|
US7794713B2
(en)
|
2004-04-07 |
2010-09-14 |
Lpath, Inc. |
Compositions and methods for the treatment and prevention of hyperproliferative diseases
|
|
KR101270829B1
(ko)
|
2004-09-23 |
2013-06-07 |
제넨테크, 인크. |
시스테인 유전자조작 항체 및 접합체
|
|
CN102618644A
(zh)
|
2004-11-18 |
2012-08-01 |
耶鲁大学 |
治疗眼病的方法和组合物
|
|
WO2006071856A2
(en)
|
2004-12-23 |
2006-07-06 |
Glycofi, Inc. |
Immunoglobulins comprising predominantly a man5glcnac2 glycoform
|
|
US8916351B2
(en)
|
2005-01-04 |
2014-12-23 |
Hitachi Chemical Co., Ltd. |
Primer generation rolling circle amplification
|
|
EP2357254A1
(en)
|
2005-02-14 |
2011-08-17 |
University of Iowa Research Foundation |
Methods and reagents for treatment and diagnosis of age-related macular degeneration
|
|
EP2570491A1
(en)
|
2005-06-08 |
2013-03-20 |
University of Pittsburgh of the Commonwealth System of Higher Education |
Susceptibility genes for age-related maculopathy (ARM) on chromosome 10q26
|
|
MX351152B
(es)
|
2005-10-08 |
2017-10-04 |
Potentia Pharmaceuticals Inc |
Compstatina y analogos de la misma para tratar trastornos oculares.
|
|
EP3299027A1
(en)
|
2005-11-04 |
2018-03-28 |
Genentech, Inc. |
Use of complement pathway inhibitors to treat ocular diseases
|
|
US20070190057A1
(en)
|
2006-01-23 |
2007-08-16 |
Jian Wu |
Methods for modulating mannose content of recombinant proteins
|
|
AR059066A1
(es)
|
2006-01-27 |
2008-03-12 |
Amgen Inc |
Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
|
|
US20080146501A1
(en)
|
2006-02-13 |
2008-06-19 |
University Of Iowa Research Foundation |
Protective complement proteins and age-related macular degeneration
|
|
JP2009531390A
(ja)
|
2006-03-31 |
2009-09-03 |
ノバルティス アクチエンゲゼルシャフト |
有機化合物
|
|
US7608261B2
(en)
|
2006-06-16 |
2009-10-27 |
Regeneron Pharmacuticals, Inc. |
VEGF antagonist formulations suitable for intravitreal administration
|
|
US20100129379A1
(en)
*
|
2006-09-25 |
2010-05-27 |
John Carpenter |
Stabilized antibody formulations and uses thereof
|
|
CN106188303A
(zh)
|
2006-11-02 |
2016-12-07 |
健泰科生物技术公司 |
人源化的抗‑d因子抗体
|
|
US20090111708A1
(en)
|
2007-05-11 |
2009-04-30 |
Seddon Johanna M |
Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk
|
|
AR066660A1
(es)
|
2007-05-23 |
2009-09-02 |
Genentech Inc |
Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
|
|
CN101796072B
(zh)
*
|
2007-05-24 |
2014-09-24 |
埃博灵克斯股份有限公司 |
用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽
|
|
WO2009029587A2
(en)
|
2007-08-24 |
2009-03-05 |
The Regents Of The University Of Michigan |
Compositions and methods for diagnosing and treating macular degeneration
|
|
EP2283163B1
(en)
|
2008-04-18 |
2015-07-08 |
Tufts Medical Center |
Polymorphisms associated with age-related macular degeneration and methods for evaluating patient risk
|
|
WO2009134709A2
(en)
|
2008-04-28 |
2009-11-05 |
Tufts Medical Center |
Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk
|
|
CR20170001A
(es)
|
2008-04-28 |
2017-08-10 |
Genentech Inc |
Anticuerpos anti factor d humanizados
|
|
CN101724144A
(zh)
|
2008-11-03 |
2010-06-09 |
北京键凯科技有限公司 |
新型的多臂聚乙二醇及其制备方法和应用
|
|
CN103333952B
(zh)
|
2008-11-05 |
2015-07-29 |
健泰科生物技术公司 |
年龄相关的黄斑变性中的遗传多态性
|
|
US20120115925A1
(en)
|
2008-12-23 |
2012-05-10 |
Massachusetts Eye And Ear Infirmary |
Allelic Variants Associated with Advanced Age-Related Macular Degeneration
|
|
JP2012514493A
(ja)
|
2009-01-02 |
2012-06-28 |
アルコン リサーチ， リミテッド |
その場で再充填可能な眼用移植物
|
|
WO2010085542A2
(en)
|
2009-01-23 |
2010-07-29 |
Novartis Ag |
Biomarkers related to age-related macular degeneration (amd)
|
|
US8399006B2
(en)
|
2009-01-29 |
2013-03-19 |
Forsight Vision4, Inc. |
Posterior segment drug delivery
|
|
WO2010132459A2
(en)
|
2009-05-11 |
2010-11-18 |
Cleveland Clinic Foundation |
Biomarkers for assessment of age-related macular degeneration
|
|
ES2827845T3
(es)
|
2009-07-02 |
2021-05-24 |
Lanzatech New Zealand Ltd |
Proceso de producción de alcohol
|
|
WO2011006161A2
(en)
|
2009-07-10 |
2011-01-13 |
The Regents Of The University Of Michigan |
Compositions and methods for diagnosing and treating macular degeneration
|
|
US20120190578A1
(en)
|
2009-08-06 |
2012-07-26 |
Washington University |
Plasma Complement Components as Expression Markers for Age-Related Macular Degeneration and Related Phenotypes
|
|
AU2010282434A1
(en)
|
2009-08-12 |
2012-03-29 |
Pure Bioscience |
Formulations and methods employing anhydrous disinfectant
|
|
US20110165648A1
(en)
|
2009-11-04 |
2011-07-07 |
Menno Van Lookeren Campagne |
Co-crystal structure of factor D and anti-factor D antibody
|
|
MX2012005791A
(es)
*
|
2009-11-19 |
2012-07-03 |
Merck Serono Sa |
Anticuerpos humanizados contra el receptor alfa de la interleucina 22 humana.
|
|
EP2507381A4
(en)
|
2009-12-04 |
2016-07-20 |
Hoffmann La Roche |
MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS AND METHODS
|
|
CN103755949B
(zh)
|
2009-12-25 |
2016-04-13 |
天津键凯科技有限公司 |
多臂聚乙二醇衍生物及其与药物的结合物和凝胶
|
|
CA2810016A1
(en)
*
|
2010-09-03 |
2012-03-08 |
Stem Centrx, Inc. |
Novel modulators and methods of use
|
|
DK2635704T3
(en)
|
2010-11-01 |
2017-06-19 |
Hoffmann La Roche |
Predicting progression to advanced age-related macular degeneration using a polygenic score
|
|
KR102001686B1
(ko)
*
|
2011-04-07 |
2019-07-18 |
암젠 인크 |
신규한 egfr 결합 단백질
|
|
CN103917556B
(zh)
|
2011-10-14 |
2018-02-06 |
霍夫曼-拉罗奇有限公司 |
抗HtrA1抗体及使用方法
|
|
JP6051998B2
(ja)
|
2012-03-30 |
2016-12-27 |
日油株式会社 |
マルチアーム型ポリエチレングリコール誘導体、その中間体及び製造方法
|
|
SMT201800503T1
(it)
*
|
2013-03-18 |
2018-11-09 |
Janssen Pharmaceuticals Inc |
Anticorpi anti-cd (ox40) umanizzati e loro usi
|
|
AU2014306867B2
(en)
|
2013-08-12 |
2017-10-26 |
Genentech, Inc. |
Compositions and method for treating complement-associated conditions
|
|
EP3761033A3
(en)
|
2013-09-06 |
2021-01-20 |
F. Hoffmann-La Roche AG |
Method for improving antibody stability
|
|
AR099625A1
(es)
*
|
2014-03-21 |
2016-08-03 |
Lilly Co Eli |
Anticuerpos de il-21
|
|
EP3137503A1
(en)
*
|
2014-05-01 |
2017-03-08 |
Genentech, Inc. |
Anti-factor d antibody variants and uses thereof
|
|
WO2017075252A1
(en)
|
2015-10-30 |
2017-05-04 |
Genentech, Inc. |
Anti-factor d antibody variant conjugates and uses thereof
|
|
US20170137535A1
(en)
|
2015-10-30 |
2017-05-18 |
Genentech, Inc. |
Anti-factor d antibody formulations
|
|
US10407510B2
(en)
|
2015-10-30 |
2019-09-10 |
Genentech, Inc. |
Anti-factor D antibodies and conjugates
|
|
HK1257425A1
(zh)
|
2015-10-30 |
2019-10-18 |
豪夫迈‧罗氏有限公司 |
测量因子d活性和因子d抑制剂效力的方法
|